AbCellera Biologics Inc. ABCL Payments to Acquire Marketable Securities
Payments to Acquire Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireMarketableSecurities.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s payments to acquire marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s payments to acquire marketable securities?
- AbCellera Biologics Inc. (ABCL) reported payments to acquire marketable securities of $166.31M in Q1 2026.
- How has AbCellera Biologics Inc.'s payments to acquire marketable securities changed year-over-year?
- AbCellera Biologics Inc.'s payments to acquire marketable securities increased by 0.8% year-over-year, from $164.99M to $166.31M.
- What is the long-term trend for AbCellera Biologics Inc.'s payments to acquire marketable securities?
- Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s payments to acquire marketable securities has grown at a -34.7% compound annual growth rate (CAGR), from $1.02B to $436.04M.
- What does payments to acquire marketable securities mean?
- This metric reflects the cash used to purchase short-term, liquid financial instruments as part of the company's treasury and cash management strategy. It indicates how the company deploys excess cash to generate interest income while maintaining liquidity.